Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia

Shock

Volumn 27, Issue 5, 2007, Pages 482-487

  Sprong, Tom ^a,b   Pickkers, Peter ^a   Geurts Moespot, Anneke ^a   Van Der Ven Jongekrijg, Johanna ^a,b   Neeleman, Chris ^a   Knaup, Marlies ^b,c   LeRoy, Didier ^b,c   Calandra, Thierry ^b,c   Van Der Meer, Jos W M ^a,b   Sweep, Fred ^a   Van Deuren, Marcel ^a,b  

^a Department of General Internal Medicine ^*  (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Cytokines; Human experimental endotoxemia; Lipopolysaccharide; Macrophage migration inhibitory factor; Neisseria meningitidis; Sepsis

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HUMAN; INNATE IMMUNITY; MALE; MENINGOCOCCEMIA; NEISSERIA MENINGITIDIS; NONHUMAN; SEPTIC SHOCK;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOKINES; ENDOTOXEMIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNITY, NATURAL; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; SHOCK, SEPTIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247239939     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000246898.65692.34     Document Type: Article

References (47)

1. Bloom BR, Bennet B: Mechanism of a reaction in vitro associated with delayed type hypersensitivity. Science 153:80-82, 1966.
2. David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 56:72-77, 1966.
3. Calandra T, Bernhagen J, Mitchell RA, Bucala R: The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179:1895-1902, 1994.
4. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA, Calandra T, Gemsa D, Donelly T, Atkins R, et al.: Migration inhibitory factor expression in experimentally induced endotoxaemia. Am J Pathol 15:453-457, 1997.
5. Calandra T, Roger T: Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791-800, 2003.
6. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH: A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 190:1375-1382, 1999.
7. Benigni F, Atsumi T, Calandra T, Metz CN, Echtenacher B, Peng T, Bucala R: The proinflammatory mediator macrophage migration inhibitory factor induces glucose catabolism in muscle. J Clin Invest 106:1291-1300, 2000.
8. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R: MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71, 1995.
9. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, Gemsa D, Donelly T, Bucula R: An essential regulatory role for the macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 93:7849-7854, 1996.
10. Roger T, David J, Glauser MP, Calandra T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414:920-924, 2001.
11. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R: MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365:756-759, 1993.
12. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR: Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189:341-346, 1999.
13. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L, Heumann D, Mannel D, Bucala R, Glauser MP: Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6:164-170, 2000.
14. Van Deuren M, Brandtzaeg P, Van der Meer JWM: Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13:144-166, 2000.
15. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C, Hoeft A, Stuber F: Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27:1412-1415, 2000.
16. Gando S, Nishihira J, Kobayashi S, Morimoto Y, Nanzaki S, Kemmotsu O: Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med 27:1187-1193, 2001.
17. Beishuizen A, Thijs LG, Haanen C, Vermes I: Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86:2811-2816, 2001.
18. Bozza FA, Gomes RN, Japiassu AM, Soares M, Castro-Faria-Neto HC, Bozza PT, Bozza MT: Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22:309-313, 2004.
19. Holten E: Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 9:186-188, 1979.
20. Sprong T, Stikkelbroeck N, van der Ley P, Steeghs L, van Alphen L, Klein N, Netea MG, van der Meer JWM, van Deuren M: Contributions of Neisseria meningitidis LPS and non-LPS to proinflammatory cytokine response. J Leukoc Biol 70:283-288, 2001.
21. Grebenschikov N, Geurts-Moespot A, De Witte H, Heuvel J, Leake R, Sweep F, Benraad T: A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type 1 (PAI-1) in breast tumor cytosols. Int J Biol Markers 12:6-14, 1997.
22. Grebenschikov N, Sweep F, Geurts-Moespot A, Piffanelli A, Foekens JA, Benraad T: An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J Immunol Methods 268:219-231, 2002.
23. Sweep CGJ, Geurts-Moespot A, Grebenchtchikov N, De Witte H, Heuvel JJTM, Schmitt M, Duffy MJ, Janicke F, Kramer MD, Foekens JA, et al.: External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer 78:1434-1441, 1998.
24. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT: Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 10:133-139, 2003.
25. Pollack MM, Ruttimann UE, Getson PR: Pediatric risk of mortality (PRISM) score. Crit Care Med 16:1110-1116, 1988.
26. van Brakel MJ, van Vught AJ, Gemke RJ: Pediatric risk of mortality (PRISM) score in meningococcal disease. Eur J Pediatr 159:232-236, 2000.
27. Mizue Y, Nishihira J, Miyazaki T, Fujiwara S, Chida M, Nakamura K, Kikuchi K, Mukai M: Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. Int J Mol Med 5:397-403, 2000.
28. Awandare GA, Hittner JB, Kremsner PG, Ochiel DO, Keller CC, Weinberg JB, Clark IA, Perkins DJ: Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with Plasmodium falciparum malaria. Clin Immunol 119:219-225, 2006.
29. Bollaert PE, Fieux F, Charpentier C, Levy B: Baseline cortisol levels, cortisol response to corticotropin, and prognosis in late septic shock. Shock 19:13-15, 2003.
30. Rothwell PM, Udwadia ZF, Lawler PG: Cortisol response to corticotropin and survival in septic shock. Lancet 337:582-583, 1991.
31. Pickkers P, Sprong T, Eijk L, Hoeven H, Smits P, Deuren M: Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 24:508-512, 2005.
32. Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G, Wong J: Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg 242:55-63, 2005.
33. Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M, et al.: Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer 107:22-29, 2003.
34. Maxime V, Fitting C, Annane D, Cavaillon JM: Corticoids normalize leukocyte production of macrophage migration inhibitory factor in septic shock. J Infect Dis 191:138-144, 2005.
35. Bruhn A, Verdant C, Vercruysse V, Su F, Vray B, Vincent JL: Effects of dexamethasone on macrophage migration inhibitory factor production in sepsis. Shock 26:169-173, 2006.
36. Spinas GA, Keller U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxemia. J Clin Invest 90:533-536, 1992.
37. Van der Poll T, de Waal Malefyt R, Coyle SM, Lowry SF: Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis 175:118-122, 1997.
38. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, ten Cate JW, van Deventer SJH: Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 184:1601-1608, 1996.
39. Lowry SF: Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 24(Suppl 1):94-100, 2005.
40. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R, van Riel PL: Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020-3029, 2005.
41. Calandra T, Spiegel LA, Metz CN, Bucala R: Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc Natl Acad Sci U S A 95: 11383-11388, 1998.
42. Riedemann NC, Guo RF, Gao H, Sun L, Hoesel M, Hollmann TJ, Wetsel RA, Zetoune FS, Ward PA: Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. J Immunol 173:1355-1359, 2004.
43. Sprong T, Moller ASWM, Bjerre A, Wedege E, Kierulf P, van Der Meer JW, Brandtzaeg P, van Deuren M, Mollnes TE: Complement activation and complement-dependent inflammation by Neisseria meningitidis occurs independent of lipopolysaccharide. Infect Immun 72:3344-3349, 2004.
44. Brandtzaeg P, Bryn K, Kierulf P, Øvstebø R, Namork E, Aase B, Jantzen E: Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy. J Clin Invest 89:816-823, 1992.
45. Ovstebo R, Brandtzaeg P, Brusletto B, Haug KB, Lande K, Hoiby EA, Kierulf P: Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 42:2980-2987, 2004.
46. Hackett SJ, Guiver M, Marsh J, Sills JA, Thomson APJ, Kaczmarski EB, Hart CA: Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child 86:44-46, 2002.
47. Garner LB, Willis MS, Carlson DL, DiMaio JM, White MD, White DJ, Horton JW, Giroir BP: Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 285:H2500-H2509, 2003.